Allergy Therapeutics PLC Completion of recruitment in PQ Grass Ph II trial (5209E)
February 12 2018 - 2:00AM
UK Regulatory
TIDMAGY
RNS Number : 5209E
Allergy Therapeutics PLC
12 February 2018
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Completion of recruitment in PQ Grass Phase II trial
Trial running ahead of schedule with data now due in early H2
2018
12 February 2018 Allergy Therapeutics plc (AIM:AGY), the fully
integrated specialty pharmaceutical group specialising in allergy
vaccines, today announces that recruitment has been completed in
its grass allergy Phase II study (G205), with results due ahead of
expectations in early H2 2018. The trial is designed to evaluate
the dose-response and safety of its ultra-short course, aluminium
free PQ Grass immunotherapy to address the cause of symptoms of
allergic rhinoconjunctivitis due to grass pollen.
The study protocol involves more than 440 patients in over 50
sites across Germany, Austria and Poland. The trial is designed to
identify the optimal efficacious cumulative dose using conjunctival
provocation testing. This type of challenge testing has recently
been used in studies for a similar subcutaneous allergoid MPL
product resulting in selection and approval of dose for use in a
phase III study.
One of the key markets for this global product is expected to be
the US. The US allergy immunotherapy market is estimated by the
Group to be worth $2 billion with potential peak grass vaccine
sales of $300-400 million per annum. If approved, the product will
be the first registered subcutaneous immunotherapy product in the
US for allergy.
Manuel Llobet, Chief Executive Officer of Allergy Therapeutics,
commented: "The completion of recruitment for all patients in our
Phase II trial is an important step in our journey towards access
to the US market in which PQ Grass has the potential to become a
convenient, best in class, ultra-short course subcutaneous
immunotherapy. We are pleased that the study is running ahead of
schedule and look forward to seeing the results later this
year."
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Philippa Gardner
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical group focussed on the treatment and diagnosis of
allergic disorders, including immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third
party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development
include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved double digit compound
annual growth since formation, employs c.500 employees and is
listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com.
About PQ Grass
PQ Grass contains three distinct components: allergoids,
micro-crystalline tyrosine (MCT) and monophosphoryl lipid A (MPL(R)
). Allergoids (natural allergens chemically modified to form
allergoids) exhibit reduced allergenicity that improves safety and
allows for delivery of higher doses. These are combined with the
depot adjuvant technology MCT to provide enhanced immune exposure
and further improved tolerability. Finally, the immune response is
specifically enhanced and directed by the adjuvant MPL(R) . MPL is
a toll-like 4 receptor (TLR4) agonist which has been extensively
used in the Group's other allergy vaccines available on the market
and in vaccines registered in the USA.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAAAFFLXPEAF
(END) Dow Jones Newswires
February 12, 2018 02:00 ET (07:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024